Abstract
A review of the findings of the past decade’s clinical trials with ß blockade provides compelling evidence for the benefits of using these drugs to treat stable chronic heart failure. In the Australia/New Zealand Heart Failure study (ANZ), treatment with carvedilol resulted in a 26% reduction in death or hospitalisation compared with placebo, additional to standard therapy of diuretics, digoxin and an ACE inhibitor [1]. In the US Carvedilol Programme, there was a 65% reduction in the risk of death, and a 53% reduction in heart failure hospitalisations in patients treated with carvedilol, compared with placebo [2]. In the Metoprolol CR/XL Randomised Intervention Trial in Heart Failure (MERIT-HF) study, treatment with metoprolol was associated with a 34% reduction in all-cause mortality compared with placebo [3]; an equivalent finding was also observed in the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) [4]. A recent meta-analysis of 25 trials totalling 6511 patients, comparing the use of ß-blockade with placebo, additional to standard therapy to treat heart failure patients, demonstrated a 36% reduction in risk of death in patients receiving ß-blockade, compared with those receiving placebo [5].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebocontrolled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–80.
Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–55.
The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7.
CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13.
Cleland JG, McGowan J, Clark A et al. The evidence for beta blockers in heart failure. BMJ 1999; 318: 824–5.
Zannad F, Braincon S, Juilliere Y et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. JACC 1999; 33: 734–42.
Packer M, Cohn JN on behalf of the Advisory Council to Improve Outcomes Nationwide in Heart Failure (ACTION-HF). Consensus Recommendations for the Management of Chronic Heart Failure. Am J Cardiol 1999; 83 (SuppI2A): 1A–79A.
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.
Fowler MB, Colucci WS, Bristow MR. Tolerability of carvedilol initiation in heart failure patients. Presented at 70th Annual Scientific Session of the American Heart Association (AHA), Anaheim, CA, USA, November 1997.
Krum H, Shusterman N, MacMahon S et al. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group. J Card Fail 1998; 4: 281–8.
Kropff S, Simon P, Hoebel W. Titration of carvedilol in patients with stable congestive heart failure: experience from an observational cohort study (291) in Germany. Eur Heart J 1998; 19: 352 (A).
Unpublished SmithKline Beecham data on file. Study Europe 272.
Unpublished Roche data on file. Study PMS Germany MF9531.
Balli E, Lucci D, Gorini M et al. Clinical variables predicting the use of beta blockers in heart failure: the BRING-UP study. Eur Heart J 1999; 20: 624.
Unpublished SmithKline Beecham data on file. Study US 257.
Unpublished Roche data on file. Study International 275.
Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability of beta-blockade in patients with chronic heart failure: The Carvedilol Open-Label Assessment (COLA) study. JACC 2000; 35: 218.
Sackner-Bernstein JD, Krum H, Goldsmith RL et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment (abstr). Circulation 1995; 92 (Suppl 1): 1–395.
Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295–1302.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Krum, H. (2001). Tolerability of Anti-Adrenergic Treatment of Congestive Heart Failure in Daily Practice. In: Rydén, L.E. (eds) Prevention of Disease Progression Throughout the Cardiovascular Continuum. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56525-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-56525-0_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62567-1
Online ISBN: 978-3-642-56525-0
eBook Packages: Springer Book Archive